Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety in Japanese patients across two global randomized phase III studies (REACH-2 and REACH).

@article{Kudo2019RamucirumabAS,
  title={Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety in Japanese patients across two global randomized phase III studies (REACH-2 and REACH).},
  author={Masatoshi Kudo and Takuji Okusaka and Kenta Motomura and Naoto Shiba and Manabu Morimoto and Satoru Seo and Yoshiyuki Wada and Shinpei Sato and Tatsuya Yamashita and Masayuki Furukawa and Takeshi Aramaki and Seijin Nadano and Kazuyoshi Ohkawa and Hirofumi Fujii and Toshihiro Kudo and Junji Furuse and Hiroki Takai and Gosuke Homma and Reigetsu Yoshikawa and Andrew X. Zhu},
  journal={Journal of Clinical Oncology},
  year={2019},
  volume={37},
  pages={320-320}
}

Topics from this paper.

Similar Papers

Loading similar papers…